← All trials
NCT00066703
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2003
- Primary completion
- Jun 1, 2014
- Completion date
- Jun 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 2672
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- International Breast Cancer Study GroupLead sponsor
- Ospedale S. Giovanni BellinzonaStudy chair
- National Cancer Institute (NCI)Collaborator
- University of CalgaryStudy chair
- University of MilanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.